Doc: nearly 200 US utilities, data center developers, and others have signed Trump's pledge to ensure AI energy use doesn't push up consumer electric bills
THE SO WHAT
AI power demand is now politically constrained, not just physically constrained — 200 utilities and data center developers signing a pledge means rate optics will shape siting and pricing. If you’re planning large AI footprints in the US, model scenarios where regulators prioritize retail bills over wholesale flexibility.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging TechBlackstone Tying Up $3 Billion AirTrunk Loan as Data Center Debt Binge Woes Grow
A A$4.3B (~$3B) underwritten loan for a single Australian data center, even as lenders worry about AI infra debt, shows capital is still flowing—but scrutiny is shifting from chips to power, utilization, and offtake quality. If you’re planning large-scale AI infra, expect tighter covenants, more questions on long-term demand, and less tolerance for speculative builds.
Deep & Emerging TechTrump administration to spend $1 billion on new border surveillance system
A $1B AI-powered border surveillance build-out is another data point that computer vision and sensor fusion are now core state infrastructure. Defense and public-sector vendors should expect procurement to favor integrated AI stacks over point sensors — and higher scrutiny on governance and civil liberties.
Deep & Emerging TechLeaving Apple, Intel, and Nvidia in the dust? Huawei could join Samsung as the only tech firms producing its own CPUs, SSDs, and DRAM
If Huawei joins Samsung as a full-stack CPU–SSD–DRAM house, the chip supply chain gets more vertically integrated and more geopolitically segmented. For OEMs and cloud buyers, that means sharper trade-offs between supply resilience and export-control exposure when you choose your silicon partners.
Some investors are valuing Elon Musk's Neuralink at $42 billion
A $42B implied valuation for Neuralink pulls brain–computer interfaces out of the fringe and into mainstream capital allocation. Health systems, device makers, and neurotech startups now have to plan for a world where invasive BCIs are treated as a serious platform bet, not a research curiosity.